top of page

A disease almost no one has heard of....yet

A short, clear introduction to the cause, history, clinical picture and inheritance of MCOPS12 — linked back to the original literature.

Syndromic microphthalmia 12 (MCOPS12) is an ultra-rare neurodevelopmental disorder caused by mutations in the retinoic acid receptor beta (RARB) gene (Srour et al. 2016).

HISTORY & PREVALENCE

It was first described in the medical literature in 2013 (Srour et al. 2013). The most recent systematic review, published in 2023, compiled clinical data from 52 individuals worldwide, making MCOPS12 one of the rarest disorders known (Caron et al. 2023). Because many children with this condition may be undiagnosed or misdiagnosed as having cerebral palsy or an unspecified neurodevelopmental disorder, the true number of people living with MCOPS12 is likely higher.

CLINICAL PICTURE

Most children with MCOPS12 show a combination of developmental eye anomalies (such as microphthalmia, meaning one or both eyes are smaller than normal), low muscle tone (hypotonia), and progressive movement disorders (dystonia and/or spasticity) that appear in the first years of life (Trieschmann et al. 2023). Some also have a global developmental delay, swallowing difficulties, and peripheral defects such as diaphragmatic anomalies or congenital heart defects. The range of symptoms is wide and varies strongly in severity, and not every child has every feature.

INHERITANCE

MCOPS12 is usually an autosomal dominant condition, meaning that a change in just one of the two copies of the RARB gene is enough to cause the disorder. In most families the gene change happens spontaneously in the affected child and is not present in the parents — this is called a de novo variant. In a small number of families the variant is inherited. A very rare recessive form, in which both copies of RARB are affected, has also been reported (Srour et al. 2013).

Facts about MCOPS12

  • An ultra-rare neurodevelopmental disorder caused by mutations in the RARB gene.

  • Also referred to as RARB-related disorder.

  • Usually an autosomal dominant condition, meaning that a mutation in just one of the two copies of the RARB gene is enough to cause the disorder.

  • Most frequent RARBvariant: p.Arg387Cys (p.R387C) - found in ~30% of diagnosed individuals

  • RARB iss as a transcription factor activated by retinoic acid, a metabolite of vitamin A, and plays a crucial role in the development of the eyes, diaphragm, heart, and brain.

  • Common clinical features include eye defects, hypotonia, progressive dystonia and/or spasticity, language delay, and feeding difficulties.

  • The severity and combination of features vary widely among affected children.

  • There is currently no approved treatment for MCOPS12.

REFERENCES

Scientific literature

SROUR ET AL. 2013

Recessive and Dominant Mutations in Retinoic Acid Receptor Beta in Cases with Microphthalmia and Diaphragmatic Hernia

 

SROUR ET AL. 2016

Gain-of-Function Mutations in RARB Cause Intellectual Disability with Progressive Motor Impairment

 

FOSTER ET AL. 2019

Retinoic acid receptor beta variant-related colonic hypoganglionosis

 

CARON ET AL. 2023

Clinical and functional heterogeneity associated with the disruption of retinoic acid receptor beta

 

TRIESCHMANN ET AL. 2023

De novo retinoic acid receptor beta (RARB) variant associated with microphthalmia and dystonia

 

REPLOGLE ET AL. 2024

A De Novo Noncoding RARB Variant Associated with Complex Microphthalmia Alters a Putative Regulatory Element

For more Information​

GetImage.png

CONTACT US

Rachel Sutherland - Side.png

Please feel free to contact me,

Rachel Niemeyer Sutherland

  • A Cure for Sophia and Friends
  • A Cure for Sophia and Friends
  • A Cure for Sophia and Friends
Be one of our Champions for a Cure! 

For more information about our cause, share your information below  

Thanks for submitting!

In Global Partnership with Cure MCOPS12

mcops_logo.png
bottom of page